<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="1fbfde64-a91e-412a-94b8-715248108c47"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use FLUOCINOLONE ACETONIDE 0.01% TOPICAL OIL safely and effectively. See full prescribing information for FLUOCINOLONE ACETONIDE 0.01% TOPICAL OIL.</content>
      <br/>
      <br/>
      <content styleCode="bold">FLUOCINOLONE ACETONIDE 0.01% Topical Oil (Scalp Oil) for topical use </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1988</content>
   </title>
   <effectiveTime value="20250514"/>
   <setId root="1159c5ff-426d-45b8-9fb4-51feb9b760c8"/>
   <versionNumber value="13"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="963900878" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-703" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-703" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-703" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-703" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="953a0209-155c-420d-8290-91cf8dddeb06"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250514"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="65162-703" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Fluocinolone Acetonide</name>
                        <formCode code="C42965" displayName="OIL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Fluocinolone Acetonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.11"/>
                              <denominator unit="mL" value="118.28 "/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLUOCINOLONE ACETONIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLUOCINOLONE ACETONIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0RE8K4LNJS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL MYRISTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N6K5787QVP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIGHT MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5TL50QU0W4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEANUT OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7L6R1SQ6M0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLETH-2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="118.28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="65162-703-86" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150922"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA201759" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150922"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" displayName="TOPICAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">
               <id root="39833a70-008e-4ebd-8e82-fc3e04bdd522"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Fluocinolone acetonide 0.01% topical oil (scalp oil) is indicated for the treatment of psoriasis of the scalp in adults.</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) is a corticosteroid indicated for the treatment of psoriasis of the scalp in adults. (1) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">
               <id root="86d4eedd-ced1-4d97-82fc-b3b70b64c27f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Fluocinolone acetonide 0.01% topical oil is for topical use only. Not for oral, ophthalmic, or intravaginal use. </paragraph>
                  <paragraph>Wet or dampen hair and scalp thoroughly. Apply a thin film of fluocinolone acetonide 0.01% topical oil on the scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight or for a minimum of 4 hours then wash hair with regular shampoo and rinse thoroughly. Use daily as needed.</paragraph>
                  <paragraph>Discontinue fluocinolone acetonide 0.01% topical oil when control of disease is achieved within 2 weeks, or contact the healthcare provider if no improvement is seen within 2 weeks.</paragraph>
                  <paragraph>Do not use fluocinolone acetonide 0.01% topical oil on the face unless directed by the healthcare provider. Do not apply to intertriginous areas due to the increased risk of local adverse reactions <content styleCode="italics">[see Adverse Reactions (6)]</content>. </paragraph>
                  <paragraph>Do not apply to the diaper area; diapers or plastic pants may constitute occlusive use <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) is not for oral, ophthalmic, or intravaginal use. (2) </item>
                           <item>Do not use on face or intertriginous areas. (2) </item>
                           <item>Apply a thin film of Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) on the wet scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight or for a minimum of 4 hours before washing off. (2) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">
               <id root="113e25f5-7d1c-47a9-b90d-7037b78650d4"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Fluocinolone acetonide 0.01% topical oil is a topical oil containing 0.01% fluocinolone acetonide, supplied in bottles containing 4 fluid ounces and with 2 shower caps. </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) is a topical oil containing 0.01% fluocinolone acetonide, supplied in bottles containing 4 fluid ounces and with 2 shower caps. (3) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">
               <id root="3e2b694e-bf48-458b-bb1c-9d91c1ea2af5"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None. </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (4)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_4e1684e1-bdaa-4046-ac6f-e2816f5fb48e">
               <id root="aae6fcde-2660-42b1-914a-2fa1ba548e6a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Endocrine System Adverse Reactions</content>:
    <list listType="unordered" styleCode="Circle">
                                 <item>Topical corticosteroids can produce reversible HPA axis suppression, Cushing’s syndrome, hyperglycemia, and glucosuria. (5.1) </item>
                                 <item>Systemic absorption may require evaluation for hypothalamic-pituitary-adrenal (HPA) axis suppression. Potent corticosteroids use on large areas, prolonged use or occlusive use, altered skin barrier, liver failure, and young age may increase systemic absorption. Modify use should HPA axis suppression develop. (5.1) </item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Local Adverse Reactions</content>: Local adverse reactions may include atrophy, striae irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis, and may be more likely with occlusive use or more potent corticosteroids. (5.2, 6.1) </item>
                           <item>
                              <content styleCode="underline">Ophthalmic Adverse Reactions</content>: May increase the risks of glaucoma and posterior subcapsular cataract. Avoid contact of DERMA-SMOOTHE/FS Scalp Oil with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation. (5.3) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_35f6fa77-7847-4d2d-ae14-07fcd46da562">
                     <id root="c8549e97-1b17-4dc7-b3b5-513389770e82"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Endocrine System Adverse Reactions</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Cushing’s syndrome, hyperglycemia, and glucosuria can result from systemic absorption of topical corticosteroids. </paragraph>
                        <paragraph>HPA axis suppression and Cushing’s syndrome have been reported in patients receiving topical corticosteroids. </paragraph>
                        <paragraph>Conditions which increase systemic absorption include the use of more potent corticosteroids, use over large surface areas, use over prolonged periods, use of occlusive dressings, altered skin barrier, liver failure, and young age. Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure. Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. The ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. </paragraph>
                        <paragraph>If HPA axis suppression is documented, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1f9a7636-d8db-43eb-9d92-5ed72d3d01cf">
                     <id root="8d9fa325-d175-4282-964e-a3047d1223b7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Local Adverse Reactions</title>
                     <text>
                        <paragraph>Local adverse reactions may occur with use of topical corticosteroids, including fluocinolone acetonide 0.01% topical oil, and may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Some local adverse reactions may be irreversible. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and <content styleCode="italics">miliaria [see Adverse Reactions (6.1)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3edfe646-95ac-4e2b-bed5-c4b7349c59da">
                     <id root="c91b18e9-500a-42f9-ac0a-e0f168fb948a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Ophthalmic Adverse Reactions</title>
                     <text>
                        <paragraph>Use of topical corticosteroids may increase the risks of glaucoma and posterior subcapsular cataract. Glaucoma and cataracts have been reported in postmarketing experience with the use of topical corticosteroid products. Avoid contact of fluocinolone acetonide 0.01% topical oil with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_946f5b20-82a5-446b-9de2-f60d0b032189">
                     <id root="9dcc5854-44b2-48fd-8161-31d620ce00a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Allergic Contact Dermatitis</title>
                     <text>
                        <paragraph>Use of topical corticosteroids can cause allergic contact dermatitis. Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a91208fd-06e2-474a-bb44-31ec2f376be3">
                     <id root="797437f5-d88d-4518-8f48-c48f74e95795"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Concomitant Skin Infections</title>
                     <text>
                        <paragraph>Use of topical corticosteroids may delay healing or worsen concomitant skin infections. Treat concomitant skin infections with an appropriate antimicrobial agent. If the infection persists unchanged, discontinue fluocinolone acetonide 0.01% topical oil until the infection has been adequately treated. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e224bcbc-1bab-4bd1-b311-05ebc69df723">
                     <id root="1fd3e9fa-5be0-4160-9604-f8ac23baf2f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Use in Peanut-Sensitive Individuals</title>
                     <text>
                        <paragraph>Use caution in prescribing fluocinolone acetonide 0.01% topical oil for peanut-sensitive individuals <content styleCode="italics">[see Description (11)].</content>
                        </paragraph>
                        <paragraph>Should signs of hypersensitivity present (wheal and flare reactions, pruritus, or other manifestations), or should disease exacerbations occur, discontinue fluocinolone acetonide 0.01% topical oil immediately and institute appropriate therapy. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9440e503-baf7-441c-991f-439bc85d32c3">
               <id root="79211e77-dc84-4adc-8642-be074872aecd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in more detail in other sections of the labeling: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Endocrine System Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (5.1)] </content>
                     </item>
                     <item>Local Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                     </item>
                     <item>Ophthalmic Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions in pediatric subjects treated for atopic dermatitis (≥ 5%) were cough (20%), rhinorrhea (13%), pyrexia (10%), telangiectasia (7%), nasopharyngitis (7%), and hypopigmentation (7%). (6.1, 6.2) </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_53a78dd1-e6e2-406f-aa93-77c0b2b3fea8">
                     <id root="171aad9f-2fde-49e0-b7ea-c89464f3deaf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>An open-label study was conducted in 29 pediatric subjects 3 months to 2 years old to assess the HPA axis by ACTH stimulation testing following use of the formulation of fluocinolone acetonide 0.01% topical oil twice daily for 4 weeks. Fluocinolone acetonide 0.01% topical oil is not approved for use in pediatric patients for the treatment of psoriasis of the scalp. The most common adverse reactions were reported in the study. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Adverse Reactions in ≥2% of Pediatric Subjects 3 Months to 2 Years of Age Treated with the Formulation of</content>
                           <content styleCode="bold">Fluocinolone Acetonide 0.01% Topical Oil</content>
                           <content styleCode="bold">, N=30*</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="1">
                           <col width="3pt1pt1pt"/>
                           <col width="175.5pt"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Cough </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6 (20)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Rhinorrhea</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4 (13)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pyrexia</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (10)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nasopharyngitis</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hypopigmentation </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Abscess </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Atopic Dermatitis </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Eczema</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hyperpigmentation</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Molluscum</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Rash</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Diarrhea </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Otitis Media </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>URI</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* Includes one subject who withdrew at Week 2</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_31cd30fc-21ba-4779-b4f1-9bc85e46e61b">
                     <id root="97405b9c-7230-4c6a-be37-ed1f95c78741"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of products containing topical corticosteroids. Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Endocrine Disorders:</content> HPA axis suppression and Cushing’s syndrome </item>
                           <item>
                              <content styleCode="italics">Eye Disorders:</content> glaucoma and cataracts </item>
                           <item>
                              <content styleCode="italics">Nervous System Disorders:</content> intracranial hypertension including bulging fontanelles, headaches, and bilateral papilledema </item>
                        </list>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d8fb27d1-edc0-46b8-9cc1-d87f6735066d">
               <id root="0d379970-8048-44d3-9f20-beec45dea5f2"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="LINK_c7ddff79-330d-427b-b47b-400ef0464579">
                     <id root="012fb10b-37c1-4c84-b5e7-b7f03a49633e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from case reports, case series, and observational studies on fluocinolone acetonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Observational studies suggest maternal use of high to super-high potency topical steroids may be associated with an increased risk of low birthweight infants. Advise pregnant women to use fluocinolone acetonide 0.01% topical oil on the smallest area of skin and for the shortest duration possible. </paragraph>
                        <paragraph>Corticosteroids can cause fetal malformations in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids cause fetal malformations after dermal application in laboratory animals. </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">
                     <id root="2db08e2c-12de-4ae1-a0ac-4a80a39a3f17"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of fluocinolone acetonide in breast milk or its effects on the breastfed infant or on milk production. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. To minimize potential exposure to the breastfed infant via breast milk, use fluocinolone acetonide 0.01% topical oil on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply fluocinolone acetonide 0.01% topical oil directly to the nipple and areola to avoid direct infant exposure<content styleCode="italics"> [see Warnings and Precautions (5.1)]. </content>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for fluocinolone acetonide 0.01% topical oil and any potential adverse effects on the breastfed infant from fluocinolone acetonide 0.01% topical oil or from the underlying maternal condition. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2a76746e-04aa-4ca6-8470-1aa0e68d79ac">
                     <id root="52f98e74-923c-4097-ac2c-d56407cdf64a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of fluocinolone acetonide 0.01% topical oil have not been established in pediatric patients with psoriasis of the scalp. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Evaluation in Peanut-Sensitive Pediatric Patients </content>
                        </paragraph>
                        <paragraph>A clinical trial was conducted to assess the safety of the formulation of fluocinolone acetonide 0.01% topical oil, which contains refined peanut oil, in patients with known peanut allergies. The trial enrolled 13 pediatric subjects with atopic dermatitis, 6 to 17 years of age. Fluocinolone acetonide 0.01% topical oil is not approved for the treatment of atopic dermatitis. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The trial evaluated the subjects' responses to both prick test and patch test utilizing refined peanut oil, the formulation of fluocinolone acetonide 0.01% topical oil and histamine/saline controls. Subjects were also treated with the formulation of fluocinolone acetonide 0.01% topical oil twice daily for 7 days. Prick test and patch test results for all 13 subjects were negative to the formulation of fluocinolone acetonide 0.01% topical oil and the refined peanut oil. One of the 9 peanut-sensitive subjects experienced an exacerbation of atopic dermatitis after 5 days of use on the formulation of fluocinolone acetonide 0.01% topical oil. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_94dfdaa6-3893-42c2-9260-ca4a11462f2f">
               <id root="bc22ba53-551c-43fd-800a-c92aa6eca345"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Fluocinolone acetonide 0.01% topical oil contains fluocinolone acetonide [(6α, 11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17 [(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use. Chemically, fluocinolone acetonide is C<sub>24</sub> H<sub>30</sub> F<sub>2</sub> O<sub>6</sub>. It has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Fluocinolone acetonide has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water. </paragraph>
                  <paragraph>Each gram of fluocinolone acetonide 0.01% topical oil contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, and refined peanut oil NF. </paragraph>
                  <paragraph>Each packaged product contains 2 shower caps. The shower cap is made of low density polyethylene material with rubber elastic.</paragraph>
                  <paragraph>Fluocinolone acetonide 0.01% topical oil is formulated with 48% refined peanut oil. The bulk refined peanut oil used in fluocinolone acetonide 0.01% topical oil is heated at 246°C (475°F) for at least 15 minutes. The refined peanut oil used in fluocinolone acetonide 0.01% topical oil is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million (ppm). </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structural formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fluocinolone-acetonide-0-01-percent-topical-oil-sc-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bccb04cc-3991-4ea2-b6f4-04a6afd0b8f3">
               <id root="ff257bb2-5c95-47b0-8b90-f8f3b72528c6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="LINK_f1abae1d-7871-43d7-bbb1-77ffe4b1ffb5">
                     <id root="4dfc526d-a0ae-4293-a31e-ce40235a9054"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in psoriasis of the scalp is unknown. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_341097fb-f403-4324-b506-0e5f01fc8f3a">
                     <id root="2c737792-f944-4b55-810f-a3565602f17f"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Vasoconstrictor Assay</content>
                        </paragraph>
                        <paragraph>Fluocinolone acetonide 0.01% topical oil is in the low to medium range of potency as compared with other topical corticosteroids in vasoconstrictor studies. However, similar blanching scores do not necessarily imply therapeutic equivalence. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression</content>
                        </paragraph>
                        <paragraph>HPA axis suppression following fluocinolone acetonide 0.01% topical oil was not assessed<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_40da22ab-9880-419c-aac4-3222230c217b">
                     <id root="b2500c65-f4c7-4ac6-9fef-351619d4c851"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may increase percutaneous absorption. The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized, primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5daa79e6-a212-4003-bec5-c4661f04ac51">
               <id root="7d8f7c8a-a238-4e6c-a8df-39e7d4ed719b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="LINK_de7b6a6c-102a-443a-8563-e9fb72cae2d9">
                     <id root="1530a922-7350-4d16-b631-5788eaa38447"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity, genotoxicity, or fertility studies were conducted with fluocinolone acetonide 0.01% topical oil. However, some corticosteroids are genotoxic in various genotoxicity tests (i.e., the in vitro human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the in vivo mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test, and the in vitro mouse lymphoma gene mutation assay). </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_995374a6-9348-42d8-aeae-912d8e71b14b">
               <id root="b9d9ab66-d7c9-4799-908a-ab984c5976de"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In a vehicle-controlled study for the treatment of psoriasis of the scalp in adults, after 21 days of treatment, 60% of patients on active treatment and 21% of patients on the drug vehicle had excellent to cleared clinical response.</paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section ID="LINK_a0b45d85-af35-4ea1-b85b-0827eb4c813b">
               <id root="3046e2c7-728c-485c-92bf-52dd03429d7f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED</title>
               <text>
                  <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) is supplied in bottles containing 4 fluid ounces and with 2 shower caps (NDC 65162-703-86). </paragraph>
                  <paragraph>Storage: Keep tightly closed. Store upright at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) <content styleCode="italics">[see USP Controlled Room Temperature]</content>. </paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7f1499bb-6eb0-433e-ad99-1e4cdeab02da">
               <id root="c246c259-94d3-4af7-a692-29c732c4e1b6"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients that fluocinolone acetonide 0.01% topical oil is for topical use only <content styleCode="italics">[see Dosage and Administration (2)]</content>. </paragraph>
                  <paragraph>Instruct patients not to apply fluocinolone acetonide 0.01% topical oil to the diaper area as diapers or plastic pants may constitute occlusive use <content styleCode="italics">[see Dosage and Administration (2)].</content>
                  </paragraph>
                  <paragraph>Advise patients to avoid use of fluocinolone acetonide 0.01% topical oil on the face, axillae, or groin unless directed by their healthcare provider <content styleCode="italics">[see Dosage and Administration (2)].</content>
                  </paragraph>
                  <paragraph>Advise patients to discontinue therapy when control of disease is achieved. Instruct patients to contact their healthcare provider if no improvement is seen within 2 weeks <content styleCode="italics">[see Dosage and Administration (2)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Endocrine System Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Instruct patients not to use other corticosteroid-containing products while using fluocinolone acetonide 0.01% topical oil without first consulting their healthcare provider <content styleCode="italics">[see Warnings and Precautions (5.1)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Ophthalmic Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to avoid contact with the eyes and in case of contact, wash eyes liberally with water. Instruct patients to tell their healthcare provider if they develop any visual symptoms <content styleCode="italics">[see Warnings and Precautions (5.3)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy and Lactation</content>
                  </paragraph>
                  <paragraph>Advise women to use fluocinolone acetonide 0.01% topical oil on the smallest area of skin and for the shortest duration possible while pregnant or breastfeeding. Advise patients that are breastfeeding not to apply fluocinolone acetonide 0.01% topical oil directly to the nipple and areola to avoid direct infant exposure <content styleCode="italics">[see Use in Specific Populations (8.1 and 8.2)]. </content>
                  </paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Amneal Pharmaceuticals</content>
                  </paragraph>
                  <paragraph>Bridgewater, NJ  08807</paragraph>
                  <paragraph>Rev. 05-2025-01</paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3d87df18-2dda-4d16-b4be-ede5d6584ea0">
               <id root="23135a7b-8c11-4dd3-b107-4200339c7dc0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fluocinolone-acetonide-0-01-percent-topical-oil-sc-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>